Tilak Healthcare, a provider of digital therapeutics, has announced an agreement with Novartis Pharma for the promotion internationally of OdySight, Tilak Healthcare’s first clinically validated mobile app for patient remote vision monitoring.
Financial terms of the deal were not disclosed.
OdySight is a smartphone app used to monitor and engage patients with chronic eye diseases associated with aging. The app is available by prescription and includes vision tests and puzzles to boost patient engagement. Adapted to patient needs, the app serves as an important link in strengthening the patient-clinician relationship.
Worldwide, 650 million people are in need of regular visual acuity assessments, according to the World Health Organization (WHO). Regular follow-ups between scheduled clinic visits using digital tools like OdySight may facilitate the improvement of patient care, particularly in the context of COVID-19.
Having successfully launched a joint promotion with Novartis France in 2019, Tilak Healthcare and Novartis Pharma wish to make OdySight well-known and accessible to many more patients by expanding the co-promotion internationally.
“We are pleased to embark on this journey alongside Novartis Pharma AG, which has a long history of providing innovative solutions for patients,” Edouard Gasser, CEO of Tilak Healthcare, said in a company news release. “Thanks to this partnership, Tilak Healthcare will make OdySight accessible to a lot more people and will help optimize the current healthcare process. The current exceptional circumstances reinforce our belief in the usefulness of clinically validated digital tools for optimizing remote patient monitoring and building tomorrow’s healthcare system.”